All 2 tracked stories fall under one category: pharma. Collegium Pharmaceutical, Inc. is most often covered alongside Xtampza ER, which appears in 2 of these 2 stories. That works out to roughly 0.8 stories per week across a 17-day span.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Collegium Pharmaceutical, Inc.
All 2 tracked stories fall under one category: pharma. Collegium Pharmaceutical, Inc. is most often covered alongside Xtampza ER, which appears in 2 of these 2 stories. That works out to roughly 0.8 stories per week across a 17-day span. Source depth averages 2 original sources per story, versus 3.6 across the same-window beat baseline. Their average consequence score of 5 runs below the beat's 6 for that window. Collegium Pharmaceutical, Inc. appears in 2 tracked Biotech stories published from February 27, 2026 through March 15, 2026.
Stories tracked
2
Per week
0.8
Sources per story
2
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 184 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Collegium Pharmaceutical, Inc.. Shared-story counts are live from our verified record — not editorial picks.
Eventide Asset Management LLC has reduced its position in Collegium Pharmaceutical, Inc. (COLL), though it maintains a significant remaining stake valued at $83.65 million. This institutional shift comes as Collegium continues to integrate recent acquisitions and navigate the complex regulatory landscape of the specialty pain management market.
Collegium Pharmaceutical's Q4 2025 results showcase a successful strategic shift toward diversification, led by the ADHD treatment Jornay PM. Simultaneously, CRA International’s earnings highlight a surging demand for specialized life sciences consulting amid a complex regulatory landscape.
Collegium Pharmaceutical, Inc. is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source
link? Report a data issue.